Difficulty: Medium
Average Score: 81%
Practice
You are evaluating a 6-year-old child with ALL on interim maintenance phase who has frequent mucositis and myelosuppression that needs frequent discontinuation of his treatment. Of the following, the MOST valuable test for this child is
Correct answer
B
Rationale
In this scenario, the most valuable test for the child with ALL experiencing mucositis and myelosuppression is pharmacogenetic testing of the thiopurine S-methyltransferase (TPMT) gene (Option B).
The rationale behind this choice is that TPMT is an enzyme responsible for metabolizing thiopurine drugs like mercaptopurine, which are commonly used in ALL treatment. Children with genetic variations leading to low TPMT activity are at higher risk for severe myelosuppression when treated with thiopurine drugs. Pharmacogenetic testing helps identify these variations, allowing for personalized dosing to avoid adverse reactions and optimize treatment outcomes.
While a complete blood count (Option A) and bone marrow study (Option D) are important in monitoring disease progression and treatment response in ALL, they do not directly address the issue of drug metabolism and adverse reactions in this context. Renal function tests (Option C) may be relevant for monitoring kidney function but are not as crucial as pharmacogenetic testing for optimizing drug therapy in this case.
Educationally, understanding the importance of pharmacogenetic testing in pediatric oncology highlights the shift towards personalized medicine to enhance treatment efficacy, minimize adverse effects, and improve patient outcomes. It emphasizes the need for comprehensive patient assessments that consider genetic factors impacting drug metabolism and response, ultimately enhancing the quality of care in pediatric oncology.
The rationale behind this choice is that TPMT is an enzyme responsible for metabolizing thiopurine drugs like mercaptopurine, which are commonly used in ALL treatment. Children with genetic variations leading to low TPMT activity are at higher risk for severe myelosuppression when treated with thiopurine drugs. Pharmacogenetic testing helps identify these variations, allowing for personalized dosing to avoid adverse reactions and optimize treatment outcomes.
While a complete blood count (Option A) and bone marrow study (Option D) are important in monitoring disease progression and treatment response in ALL, they do not directly address the issue of drug metabolism and adverse reactions in this context. Renal function tests (Option C) may be relevant for monitoring kidney function but are not as crucial as pharmacogenetic testing for optimizing drug therapy in this case.
Educationally, understanding the importance of pharmacogenetic testing in pediatric oncology highlights the shift towards personalized medicine to enhance treatment efficacy, minimize adverse effects, and improve patient outcomes. It emphasizes the need for comprehensive patient assessments that consider genetic factors impacting drug metabolism and response, ultimately enhancing the quality of care in pediatric oncology.